InvestSMART

Arovella Therapeutics Limited (ASX: ALA) - Share Price

Current share price for ALA : $0.054 0.001 (1.89%)+

Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.

ALA General Information +

ASX Code ALA
Website http://www.arovella.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 65
ALA Share Price $0.054
Day High $0.054
Day Low $0.053
Last Close $0.053
ALA Share Price Movement $0.00 ( 1.89% )
Prices as at 16:40, 25 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Arovella Therapeutics Limited (ALA) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Arovella Therapeutics Limited (ALA) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Arovella Therapeutics Limited (ALA) price-sensitive announcements

ALA - Appendix 4E and Annual Report
The Arovella Therapeutics Limited Annual Report for the year ending 30 June 2026 highlight
Arovella Therapeutics Limited (ALA)
20 Aug 2026 | 11:27 AM
ALA - Quarterly Activities/Appendix 4C Cash Flow Report
Arovella Therapeutics Limited has advanced its lead product, ALA-101, towards clinical eva
Arovella Therapeutics Limited (ALA)
27 Jul 2026 | 12:15 PM
ALA - Arovella Appoints Acting CEO
Arovella Therapeutics Limited, a company listed on the ASX under the code ALA, announced t
Arovella Therapeutics Limited (ALA)
7 May 2026 | 8:24 AM
ALA - Board Refresh and CEO Resignation
Arovella Therapeutics Ltd announced significant changes to its board and executive leaders
Arovella Therapeutics Limited (ALA)
4 May 2026 | 10:00 AM

Arovella Therapeutics Limited (ALA) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 2026 ESG Report 17 Sep 2026 8:56AM $0.059 $0.054 fallen by 8.47%
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 Notification of 2026 AGM Date 9 Sep 2026 8:21AM $0.060 $0.054 fallen by 10%
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 Clinical manufacturing batch released, first site activated 7 Sep 2026 9:00AM $0.061 $0.054 fallen by 11.48%
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 Corporate Governance Statement 20 Aug 2026 11:31AM $0.064 $0.054 fallen by 15.63%
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 Appendix 4G 20 Aug 2026 11:28AM $0.064 $0.054 fallen by 15.63%
Arovella Therapeutics Limited (ALA)
ORDINARY FULLY PAID
Health Care $65 Appendix 4E and Annual Report 20 Aug 2026 11:27AM $0.064 $0.054 fallen by 15.63%

ALA Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$6.92 -$0.60 -14.70% 0.00 0.00 0.00% 0.0%
2025A -$7.51 -$0.70 -26.90% 0.00 0.00 0.00% 0.0%
2024A -$8.75 -$0.90 -23.10% 0.00 0.00 0.00% 0.0%

ALA Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Arovella Therapeutics Limited (ALA) $68M -0.1471 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Clarity Pharmaceuticals Ltd (CU6) $787M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,613M -0.7857 0.2462 0.9655 88.5690 71.0690 36.1579 0.00% 1.60% 1.89%

ALA Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 4.53 0.00
Market 0.33 13.80 1.17 0.79
Sector 0.68 30.70 2.70 2.03

ALA Directors

Name Position Start Date
Mr Mark P Diamond Non-Executive Director 28 Apr 2026
Dr Michael S Perry Non-Executive Director 28 Apr 2026
Dr Michael Joseph Thurn Non-Executive Director 28 Apr 2026
Mr David John Williams Non-Executive Director, Non-Executive Chairman 28 Apr 2026

Arovella Therapeutics Limited (ALA) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
9 Jun 2026 WILLIAMS, David Buy Indirect Shares 200,000 $0.067 $13,400.000
12 Nov 2025 BARTON, Debora Exercise Options 1,013,333 $0.052 $52,693.316
13 Oct 2025 BAKER, Michael Exercise Options 1,617,021 $0.075 $121,276.575

See all changes in directors' interest & trades for Arovella Therapeutics Limited (ALA) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ALA Management

Name Position
Nicole Louise van der Weerden Acting Chief Executive Officer
Lachie Mallia Chief Financial Officer,Company Secretary

ALA Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Arovella Therapeutics Limited (ALA). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
0 (0%) n/a

ALA Calendar of Events

Date Event
19 August 2027 Report (Annual)
19 August 2027 Report (Prelim)
18 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.